SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending amid escalating geopolitical tensions in the Middle East, triggered by drone strikes on oil facilities and disrupted shipping in the Strait of Hormuz that are pushing up energy prices. The community is actively discussing a potential massive short squeeze and parabolic run for this low-float oil stock, drawing comparisons to previous energy crises and expecting significant upside.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending after announcing a $10M strategic investment and partnership with World View to develop layered ISR solutions combining high-altitude balloons and drones. This news is fueling significant community discussion around the stock's substantial short interest and potential for a squeeze, amid broader geopolitical tensions driving demand for advanced defense technology.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amid escalating geopolitical tensions, driving intense community discussion around its attack-capable drones and their relevance to modern warfare. Investors are closely watching its participation in the Drone Dominance Program and anticipating updates from its upcoming Innovation Day.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to NVIDIA's increasing focus on photonics for AI data centers, amplifying discussions around POET's disruptive optical interconnect technology. The community is actively debating its potential for significant hyperscaler partnerships and a strong revenue ramp, with many anticipating pivotal announcements leading up to the OFC conference.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Escalating Middle East tensions, including a reported drone strike on Saudi Arabia's largest oil refinery and threats of closure for the Strait of Hormuz, are driving a surge in Battalion Oil Corp. The community is actively discussing the potential for a significant short squeeze and continued upward momentum for BATL and other low-float energy stocks amid rising crude prices.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending amid intensifying Middle East geopolitical tensions, with discussions centered on potential Strait of Hormuz disruptions and Qatar's LNG plant shutdown, leading many to view the integrated energy giant as a direct beneficiary of surging oil and natural gas prices.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending following its new multi-year U.S. brewing and distribution partnership with Carlsberg Group, generating mixed community reactions as some see it as a significant diversification, while others remain highly critical, demanding focus on U.S. cannabis reform and citing concerns over market manipulation and leadership.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is surging after a strong Q4 earnings report and positive outlook, coming amidst escalating geopolitical tensions in the Middle East and Strait of Hormuz that are tightening global LNG supply. The community is discussing the company's favorable position as a key U.S. LNG exporter and the potential for a significant short squeeze.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending as community discussion vigorously debates the recent US military strikes in Iran, with supporters hailing President Trump's decisive action against perceived threats, while critics allege it is an "illegal war" and a distraction from controversies like the "Epstein files."

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is surging on a significant earnings beat and robust guidance for 800G/1.6T transceivers, driven by strong hyperscale data center demand and analyst upgrades within the burgeoning AI and photonics sector. The community is actively debating its valuation and future growth prospects against concerns over execution risk and potential dilution from a recent stock offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as monotherapy.</li><li>In combination with the anti-PD-1 therapy, the treatment reduced the volume of the primary tumor by 73%.</li><li>In patients with lung metastases, Kazia stated that NDL2, combined with anti-PD-1 therapy, reduced the primary tumor’s volume by 50%.</li></ul><p>Kazia Therapeutics Inc.’s (KZIA) shares rose more than 6% in Friday’s pre-market trade after the company announced new preclinical and translational data for NDL2, a protein degrader.</p><p>The Sydney, Australia-based oncology-focused pharmaceutical company stated that across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity. This includes the combination of NDL2 with anti-PD-1 therapy, which uses monoclonal bodies such as nivolumab or pembrolizumab to block the PD-1 protein on T-cells.</p><p>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/KZIA">Kazia Therapeutics</a> was in the ‘bullish’ territory at the time of writing, while message volume was at ‘high’ levels.</p><h2 class="st-heading-2">Highlights Of New NDL2 Data</h2><p>Kazia stated that in murine triple-negative breast cancer (TNBC) preclinical models, NDL2 reduced primary tumor volume by 49% as monotherapy. In combination with the anti-PD-1 therapy, the treatment reduced the volume of the primary tumor by 73%.</p><p>In patients with lung metastases, Kazia stated that NDL2, combined with anti-PD-1 therapy, reduced the primary tumor’s volume by 50%.</p><p>The company added that no toxicity or hemolysis was observed, while noting that the immune checkpoint function at the cell surface was preserved, and the plasma stability was favorable.</p><h2 class="st-heading-2">What Is NDL2 Aimed At?</h2><p>Kazia is currently developing the NDL2 protein degrader to selectively eliminate nuclear PD-L1 (Programmed Death-Ligand 1).</p><p>PD-L1 is a protein found on the surface of many cancer cells as well as some normal cells. The protein helps these cells evade the immune system.</p><p><a href="https://stocktwits.com/symbol/KZIA">KZIA stock</a> is down 6% year-to-date and 12% over the past 12 months.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sofi-stock-rises-after-sofi-technologies-reports-1b-quarterly-revenue-first-time/cmySKHPR4ST"><strong>SOFI Stock Rises Pre-Market After SoFi Technologies Reports $1B Quarterly Revenue For The First Time</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Representative image of a trending stock chart.

KZIA Stock Is Rising Today — What Does Its Data For Nuclear PD-L1 Degrader Show?

Kazia stated that across multiple preclinical models and patient-derived samples, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity.

Equity

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear...

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer Kazia Therapeutics Reports...

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End Kazia Therapeutics to Participate in J.P. Morgan Healthcare...

Is the Market Bullish or Bearish on Kazia Therapeutics Ltd?

Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Kazia Therapeutics Regains Full Nasdaq Listing Compliance Kazia Therapeutics Regains Full Nasdaq Listing Compliance PR Newswire SYDNEY, Dec. 22, 2025 Restoration of Nasdaq compliance follows $50...

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations...

What's Going On With Cancer Firm Kazia Therapeutics

Kazia announced a private placement of $50 million in equity securities. Proceeds will fund clinical development and extend cash runway.read more...

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities PR Newswire...

<ul class="summary-bullets"><li>The patient remains on therapy and under active clinical monitoring, the company said.</li><li>In October, Kazia had announced that it observed an 86% reduction in tumor burden after only three weeks of treatment in the same patient.</li><li>Kazia also raised concerns on Tuesday regarding a potential suspension or delisting of its shares from the Nasdaq.</li></ul><p>Shares of cancer drug developer Kazia Therapeutics Limited (KZIA) were in the spotlight on Wednesday after the company said that a stage IV triple-negative breast cancer patient treated with a combination of its lead program Paxalisib with Pembrolizumab and standard chemotherapy has achieved an initial immune-complete response.</p><p>An immune-complete response means the complete disappearance of all signs of cancer following immunotherapy. It is also known as complete remission.</p><p>KZIA shares traded 42% higher on Wednesday morning at the time of writing.</p><h2 class="st-heading-2">Data And Takeaways</h2><p>As per Kazia, complete responses in stage IV metastatic TNBC are exceedingly uncommon and may suggest enhanced biological activity of the combination regimen, warranting continued follow-up.</p><p>In October, Kazia had announced that it observed an 86% reduction in tumor burden after only three weeks of treatment in the same patient. After about three months of therapy, a scan performed demonstrated complete metabolic resolution of all previously identified lesions, consistent with an initial immune-complete response, the company said.</p><p>The patient remains on therapy and under active clinical monitoring, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/kazia-therapeutics-achieves-initial-icr-immune-complete-response-in-metastatic-tnbc-and-delivers-q4-business-update-with-breakthroughs-across-breast-cancer-immuno-oncology-and-gbm-regulatory-strategy-302618635.html">added</a>. Kazia now plans to conduct a follow-up scan to confirm the initial scan.</p><h2 class="st-heading-2">Executive Commentary</h2><p>"Observing an initial complete response in a patient with metastatic triple-negative breast cancer is an extremely encouraging clinical finding," said CEO John Friend.</p><p>Paxalisib was licensed from Genentech in late 2016 and is being developed to treat multiple forms of cancer. The company now intends to request a meeting with the U.S. Food and Drug Administration to discuss the overall survival Paxalisib findings from its completed clinical studies and to discuss the elements needed for an application submission for Paxalisib in newly diagnosed glioblastoma.</p><h2 class="st-heading-2">Delisting Concerns</h2><p>Kazia on Tuesday also raised concerns about a potential suspension or delisting of its shares from Nasdaq, as it is not in compliance with certain listing rules. The company said it intends to request a hearing before a Nasdaq panel in a timely manner to stay any suspension or delisting action pending the outcome of the hearing.</p><p>The company is now also evaluating corporate and market-based options to regain compliance.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KZIA">KZIA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.</p><figure class="image"><img style="aspect-ratio:585/56;" src="data:image/png;base64,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" width="585" height="56" alt="KZIA's Sentiment Meter and Message Volume as of 9:23 a.m. ET on Nov. 19, 2025 | Source: Stocktwits"><figcaption>KZIA's Sentiment Meter and Message Volume as of 9:23 a.m. ET on Nov. 19, 2025 | Source: Stocktwits</figcaption></figure><p>KZIA stock is down by 8% this year and by about 71% over the past 12 months.</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alkermes-to-acquire-avadel-for-up-to-2.37-billion-after-lundbeck-proposal/cLPoIyoREB2">Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Rising stock market chart on a trading board background.

KZIA Stock Soars After Stage IV Cancer Patient Shows Initial Complete Remission On Its Drug Combination

Kazia now plans to conduct a follow-up scan to confirm the initial scan. 

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

KZIA
Kazia Therapeutics

Feed

News

Sentiment

Fundamentals

Info

Latest KZIA News

KZIAKazia Therapeutics